These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 2855903)

  • 21. [Pathohistologic changes in aortocoronary venous grafts].
    Vucković D; Vucković N
    Med Pregl; 1995; 48(9-10):305-9. PubMed ID: 8628184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [PTCA for completely occluded saphenous aortocoronary graft].
    Yasuura K; Okamoto H; Matsuura A; Moriya H; Abe T; Yoshida M; Ogawa H; Seki A; Sakai K; Hoshino M
    Kyobu Geka; 1988 Aug; 41(9):741-5. PubMed ID: 2977809
    [No Abstract]   [Full Text] [Related]  

  • 23. The comparison of platelet activity between patients with patent vs. occluded coronary artery bypass grafts.
    Osmancik PP; Bednar F; Móciková H; Stros P; Jirasek K; Straka Z; Widimsky P
    Thromb Res; 2007; 120(4):523-9. PubMed ID: 17303221
    [No Abstract]   [Full Text] [Related]  

  • 24. Non-viral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins.
    Tabuchi N; Shichiri M; Shibamiya A; Koyama T; Nakazawa F; Chung J; Hirosawa S; Sunamori M
    Eur J Cardiothorac Surg; 2004 Nov; 26(5):995-1001. PubMed ID: 15519195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relation between intraoperative blood flow measurements and graft patency afer aortocoronary bypass surgery].
    Meyer B; Pfisterer M; Grädel E; Hasse J; Stulz P; Wolff G; Skarvan K; Schmitt HE; Burkart F
    Schweiz Med Wochenschr; 1985 Nov; 115(45):1622-4. PubMed ID: 3878590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombomodulin and thrombin localization on the vascular endothelium; their internalization and transcytosis by plasmalemmal vesicles.
    Horvat R; Palade GE
    Eur J Cell Biol; 1993 Aug; 61(2):299-313. PubMed ID: 8223719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can aortocoronary and peripheral venous bypass graft patency be improved by the administration of pentoxifylline on a long-term basis?
    Angelides NS; Minas C
    Cardiologia; 1999 Dec; 44(12):1059-64. PubMed ID: 10687256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Distribution of thrombomodulin in human tissues and characterization of thrombomodulin in plasma].
    Ishii H; Nakano M; Tsubouchi J; Kazama M; Majerus PW
    Nihon Ketsueki Gakkai Zasshi; 1988 Nov; 51(7):1228-33. PubMed ID: 2851912
    [No Abstract]   [Full Text] [Related]  

  • 29. Endothelin in coronary artery disease.
    Pernow J
    Scand Cardiovasc J; 2004 Oct; 38(5):257-8. PubMed ID: 15513306
    [No Abstract]   [Full Text] [Related]  

  • 30. Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo.
    Okada SS; Golden MA; Raghunath PN; Tomaszewski JE; David ML; Kuo A; Kariko K; Barnathan ES
    Thromb Haemost; 1998 Jul; 80(1):140-7. PubMed ID: 9684800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Course of angina 1 to 12 years after aortocoronary bypass surgery related to changes in grafts and native coronary arteries.
    Campeau L; Enjalbert M; Lespérance J; Bourassa MG
    Can J Surg; 1985 Nov; 28(6):496-8. PubMed ID: 3877556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
    Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
    Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular markers of hemostatic mechanisms--clinical significance of the measurement of plasma thrombomodulin].
    Ishii H; Uchiyama H; Hiraishi S; Nakano M; Tsubouchi J; Kazama M; Tanaka A
    Rinsho Byori; 1989 Mar; 37(3):266-71. PubMed ID: 2545950
    [No Abstract]   [Full Text] [Related]  

  • 34. [Metabolism of thrombomodulin].
    Ishii H; Nakano M; Uchiyama H; Kazama M
    Rinsho Byori; 1989 Apr; Spec No 81():143-8. PubMed ID: 2547090
    [No Abstract]   [Full Text] [Related]  

  • 35. Release of tissue plasminogen activator during coronary angioplasty.
    Weyne A; de Buyzere M; Clement D; Baele G; Leroux-Roels G
    Lancet; 1990 Mar; 335(8690):658. PubMed ID: 1969029
    [No Abstract]   [Full Text] [Related]  

  • 36. Tissue-type plasminogen activator release: new frontiers in endothelial function.
    Muldowney JA; Vaughan DE
    J Am Coll Cardiol; 2002 Sep; 40(5):967-9. PubMed ID: 12225724
    [No Abstract]   [Full Text] [Related]  

  • 37. Activated protein C resistance and graft occlusion after coronary artery bypass surgery.
    Eritsland J; Gjønnes G; Sandset PM; Seljeflot I; Arnesen H
    Thromb Res; 1995 Jul; 79(2):223-6. PubMed ID: 7676409
    [No Abstract]   [Full Text] [Related]  

  • 38. Letter by Brown and Pretorius regarding article, "effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients".
    Brown NJ; Pretorius M
    Circulation; 2009 Nov; 120(19):e159; author reply e160. PubMed ID: 19901200
    [No Abstract]   [Full Text] [Related]  

  • 39. It is time to contend with the endothelial consequences of prehypertension.
    Van Guilder GP
    J Hum Hypertens; 2015 Aug; 29(8):457-8. PubMed ID: 25566875
    [No Abstract]   [Full Text] [Related]  

  • 40. Abnormalities of thrombomodulin and tissue plasminogen activator in occluded aortocoronary grafts detected by immunohistochemistry.
    Brody JI; Pickering NJ; Fink GB
    Trans Assoc Am Physicians; 1988; 101():79-87. PubMed ID: 2855903
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.